Latest Buprenorphine Stories
Enteric-Coated Buprenorphine Product Candidates (BuTab, REL-1028) to be Compared with Marketed Intravenous and Sublingual Formulations NEW YORK, March 24, 2015 /PRNewswire/ -- Relmada
A new form of Naltrexone, Vivitrol, has been proven effective in treating nearly every patient prescribed the opiate blocking medication by the Washington County Health Department, according to
Harbor Village Detox comments on the effectiveness of naltrexone, which is a non opiate based drug helping drug addicts to overcome heroin addiction and opiate abuse.
Novel product candidate being developed for the treatment of neuropathic pain demonstrates good safety profile even at higher doses NEW YORK, March 17, 2015 /PRNewswire/ -- Relmada
2014 - A Year of Many Significant Milestones, with More Expected for 2015, as BDSI Continues its Growth as an Integrated Specialty Pharmaceutical Company RALEIGH, N.C., March 16, 2015 /PRNewswire/
While methadone is often prescribed for opioid dependence or as a painkiller, Novus Medical Detox Center cautions that it can lead to addiction, workplace issues and overdose deaths--spotlighting the
Suboxone helps addicts transition from using heroin to abstaining from opiates entirely; according to a recent article by Springfield News Sun, suboxone has been banned in springfield jails, which
POTTERS BAR, England and PITTSBURGH, March 11, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Mylan Inc. today announced the U.S.
Offers additional option for physicians and patients to tailor maintenance treatment of opioid dependence MORRISTOWN, N.J., March 6, 2015 /PRNewswire/ -- Orexo US, Inc.
Panel of experts brings Relmada outstanding experience in diverse range of areas critical to the development of innovative pain therapeutics NEW YORK, March 5, 2015 /PRNewswire/ -- Relmada